GlassScriptPhysician profile
Ravi N Sinha
NPI 1134184328
$2,083.86
in general payments reported to CMS, 2019-2025
26 companies · $486 in 2025
The $486 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2021: $42.92 · 2022: $206 · 2023: $476 · 2024: $682 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,643.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $546.52 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $218.53 | 2023-2025 | Tepezza, Evenity, Prolia |
| Amneal Pharmaceuticals LLC | $164.03 | 2022-2025 | Unithroid |
| Ethicon US, LLC | $122.69 | 2019 | |
| Eisai INC. | $120.81 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.63 | 2022-2025 | Jardiance |
| Ascendis Pharma Endocrinology INC | $111.42 | 2024-2025 | Yorvipath |
| Sequel Med Tech, LLC | $89.24 | 2025 | Twiist |
| Horizon Therapeutics Plc | $86.99 | 2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $69.92 | 2022-2023 | |
| Recordati_rare_diseases_inc. | $67.80 | 2021-2025 | Isturisa, Signifor Lar |
| Novo Nordisk INC | $40.73 | 2019-2025 | |
| Cequr Corporation | $40.63 | 2023-2024 | Cequr Simplicity |
| Abbott Laboratories | $38.89 | 2022-2023 | Freestyle Libre 3 |
| Abbvie INC. | $30.08 | 2021-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $27.84 | 2024 | Crysvita |
| Xeris Pharmaceuticals, INC. | $23.92 | 2022 | |
| Medtronic Minimed, INC. | $23.58 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.22 | 2022 | |
| Neurocrine Biosciences, INC. | $20.47 | 2025 | |
| Mannkind Corporation | $18.64 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.42 | 2022 | |
| Ascensia Diabetes Care US INC. | $18.11 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $17.84 | 2024 | Uptravi |
| Medtronic, INC. | $16.47 | 2024 | Minimed 780g |
| Pfizer INC. | $16.44 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.